NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

Interventional Procedures Advisory Committee (IPAC) meeting minutes

**Minutes:** Confirmed

**Date and time:** Thursday, 10 November 2022

**Location:** Via Zoom

# Committee members present

1. Professor Tom Clutton-Brock [Chair] Present for all items
2. Professor Colin Howie [Vice Chair] Present for all items
3. Dr Charlotta Karner Present for all items
4. Ms Dawn Lee Present for all items
5. Professor Dhiraj Tripathi Present for all items except item 5 (part 2)
6. Mr James Tysome Present for items 7, 8, and 9
7. Dr Jon Bell Present for items 3, 4, 5, 6, 7, and 8 (part 1)
8. Dr Jurjees Hasan Present for all items
9. Miss Karen Nugent Present for items 3, 4, 5, and 6
10. Mr Kieran Murphy Present for items 3, 4, 5, and 6
11. Ms Maria Parsonage Present for items 5, 6, 7, 8, and 9
12. Professor Matt Bown Present for all items
13. Mr Matthew Metcalfe Present for all items
14. Mr Mustafa Zakkar Present for all items
15. Mr Patrick Farrell Present for all items
16. Dr Paula Whittaker Present for all items
17. Mrs Sally Brearley Present for items 3, 4, 5, 6, and 7
18. Dr Stuart Smith Present for all items
19. Ms Veena Soni Present for items 3 (part 1), 5, 6, 7, 8, and 9

# Committee Apologies

1. Dr Greg Irving
2. Mr Mahmoud Elfar
3. Mr Marwan Habiba
4. Professor Tim Jackson
5. Professor Tim Kinnaird

# NICE staff present:

Dr Alan Ashworth – Consultant Clinical Advisor, IPP

Anna Sparshatt – Senior Editor, Publishing

Amy Crossley – HTA Advisor, IPP

Anastasia Chalkidou – Associate Director, IPP

Benjamin Pearce – Senior Medical Editor, Publishing

Carl Jackson – Assistant Project Manager, Technology Appraisals

Charlie Campion – Project Manager, IPP

Deonee Stanislaus – Coordinator, IPP

Emilene Coventry – Senior Medical Editor, Publishing

Helen Barnett – Senior Medical Editor, Publishing

Helen Crosbie – Public Involvement Advisor, Public Involvement Programme

Helen Gallo – Senior Health Technology Assessment Analyst

Professor John Powell – Consultant Clinical Advisor, IPP

Lakshmi Mandava – Health Technology Assessment Analyst

Oyewumi Afolabi - PASLU Technical Analyst, Commercial liaison team

Rosalee Mason – Coordinator, Corporate Office

Sammy Shaw – Associate Health Technology Assessment Analyst, IPP

Suzi McFall – Specialist Registrar, Managed Access

Xia Li – Health Technology Assessment Analyst

Zoe Jones – Administrator, IPP

# External group representatives present:

Anthony Ignagni, Synapse Biomedical Inc. Present for item 3

Moustapha Diop, Synapse Biomedical Inc. Present for item 3

David Mason, OrthoPediatrics Present for item 4

Daphna Zaarorr Regev, OrthoPediatrics Present for item 4

Nilesh Patel, Boston Scientific Present for item 7

Susan Rhodes, Boston Scientific Present for item 7

Dr Robin Correa, Avanos Present for item 7

Dr Carolyn Graziano, Avanos Present for item 7

Tom Brown, Palette Life Sciences Present for item 8

Nicholas Cooper, Palette Life Sciences Present for item 8

Emily Woodward, Boston Scientific Present for item 8

Harvey Galvin, AngioDynamics Present for item 9

# Clinical & patient experts present:

Ben Messer, Consultant in Critical Care Medicine and Home Ventilation, Newcastle upon Tyne Hospitals NHS Foundation Trust Present for item 3

Kesava Mannur, Consultant Surgeon, The London Clinic Present for item 3

Julian Leong, Consultant Spinal Surgeon, Royal National Orthopaedic Hospital Present for item 4

Stephanie Clark, Chair of the Trustees, Scoliosis Association UK (SAUK) Present for item 4

Thomas Haag, Consultant in Pain Management, Betsi Cadwaladr University Health Board Present for item 7

Mark Emberton, Dean UCL Faculty of Medical Sciences, UCL and UCLH NHS Trust Present for item 9

1. Introduction to the meeting
   1. The chair welcomed members of the committee and other attendees present to the meeting.
2. News and announcements
   1. The chair encouraged the committee members that attended the IPAC away day to complete the feedback form.
   2. The chair informed the committee that Colin Howie will be retiring in March. NICE are looking to recruit for the vice-chair position. Any committee members who are interested in the position will need to let the chair or the Interventional Procedures team know.
3. NNP of IP746/3 Intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure caused by high spinal cord injuries
   1. Part 1 – Open session
      1. The Chair welcomed the invited clinical and patient experts, external group representatives, members of the public and company representatives from Synapse Biomedical Inc.
      2. The Chair asked all committee members to declare any relevant interests in relation to the item being considered.

* No conflicts of interest were declared for the technology.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
  + 1. The Chair then introduced Jon Bell, who gave a presentation on the safety and efficacy of Intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure caused by high spinal cord injuries.
  1. Part 2 – Closed session

Company representatives, clinical and patient experts and members of the public were asked to leave the meeting: 9:55.

* + 1. The committee then made its provisional recommendations on the safety and efficacy of the procedure. The committee decision was reached through a vote by members.
    2. The committee asked the NICE technical team to prepare the Consultation Document [IPCD] in line with their decisions.
  1. A document explaining the draft recommendations will be available here: <https://www.nice.org.uk/process/pmg28/chapter/draft-recommendations>

1. NNP of IP1925 Minimally invasive deformity correction system for the treatment of adolescent idiopathic scoliosis
   1. Part 1 – Open session
      1. The Chair welcomed the invited clinical and patient experts, external group representatives, members of the public and company representatives from OrthoPediatrics.
      2. The Chair asked all committee members to declare any relevant interests in relation to the item being considered.

* No conflicts of interest were declared for the technology.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
  + 1. The Chair then introduced Dawn Lee, who gave a presentation on the safety and efficacy of Minimally invasive deformity correction system for the treatment of adolescent idiopathic scoliosis.
  1. Part 2 – Closed session

Company representatives, clinical and patient experts and members of the public were asked to leave the meeting: 11:33.

* + 1. The committee then made its provisional recommendations on the safety and efficacy of the procedure. The committee decision was reached by consensus.
    2. The committee asked the NICE technical team to prepare the Consultation Document [IPCD] in line with their decisions.

A document explaining the draft recommendations will be available here: <https://www.nice.org.uk/process/pmg28/chapter/draft-recommendations>

1. Public Consultation comments of IP1865 Transvenous obliteration for gastric varices
   1. Part 1 – Open session
      1. The Chair welcomed the invited members of the public.
      2. The Chair asked all committee members to declare any relevant interests in relation to the item being considered.

* Dhiraj Tripathi declared a financial interest as he has received speaker fees from Gore Medical and is the chief investigator of a trial involving a comparator to the procedure.
* It was agreed that his declaration would prevent Dhiraj Tripathi from participating in part 2 of the discussion for this procedure.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
  + 1. The Chair then summarised the comments received during the consultation on the draft guidance for Transvenous obliteration for gastric varices.
    2. The Chair introduced the key themes arising from the consultation responses to the Interventional Procedures Consultation Document [IPCD] received from consultees, commentators and through the NICE website.
  1. Part 2 – Closed session

Company representatives, clinical and patient experts and members of the public were asked to leave the meeting: 12:12.

* + 1. The committee then made its provisional recommendations on the safety and efficacy of the procedure. The committee decision was reached by consensus.

The committee asked the NICE technical team to prepare the Final Document [FIPD] in line with their decisions.  
  
A document explaining the final recommendations is available here: <https://www.nice.org.uk/process/pmg28/chapter/the-production-of-guidance>

1. Briefs of IP1315/2 Biodegradable subacromial spacer insertion for rotator cuff tears
   1. Part 1 – Closed session
      1. The Chair asked all committee members to declare any relevant interests in relation to the item being considered.

* Colin Howie declared a non-specific professional interest as his department has received research funds from Stryker.
* It was agreed that his declaration would not prevent Colin Howie from participating in this section of the meeting.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
  + 1. The Chair then introduced Colin Howie, who gave a presentation on the safety and efficacy of Biodegradable subacromial spacer insertion for rotator cuff tears.
    2. The committee approved the content of the scope as adequate for evaluation of this procedure.

1. NNP of IP1914 Radiofrequency denervation for osteoarthritic knee pain
   1. Part 1 – Open session
      1. The Chair welcomed the invited members of the public and company representatives from Avanos and Boston Scientific.
      2. The Chair asked all committee members to declare any relevant interests in relation to the item being considered.

* Dawn Lee declared a non-financial professional interest as she worked with Boston Scientific over 10 years ago producing a cost-effectiveness analysis for their Watchman device when she was with her previous company.
* It was agreed that her declaration would not prevent Dawn Lee from participating in this section of the meeting.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
  + 1. The Chair then introduced Maria Parsonage, who gave a presentation on the safety and efficacy of Radiofrequency denervation for osteoarthritic knee pain.
  1. Part 2 – Closed session

Company representatives, clinical and patient experts and members of the public were asked to leave the meeting: 13:59.

* + 1. The committee then made its provisional recommendations on the safety and efficacy of the procedure. The committee decision was reached through a vote by members.
    2. The committee asked the NICE technical team to prepare the Consultation Document [IPCD] in line with their decisions.

A document explaining the draft recommendations will be available here: <https://www.nice.org.uk/process/pmg28/chapter/draft-recommendations>

1. Public Consultation comments of IP1316/2 Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer
   1. Part 1 – Open session
      1. The Chair welcomed the invited members of the public and company representatives from Palette Life Sciences and Boston Scientific.
      2. The Chair asked all committee members to declare any relevant interests in relation to the item being considered.

* No conflicts of interest were declared for the technology.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
  + 1. The Chair then introduced Matt Bown, who summarised the comments received during the consultation on the draft guidance for Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer.
    2. The Chair introduced the key themes arising from the consultation responses to the Interventional Procedures Consultation Document [IPCD] received from consultees, commentators and through the NICE website.
  1. Part 2 – Closed session

Company representatives, clinical and patient experts and members of the public were asked to leave the meeting: 14:59.

* + 1. The committee then made its provisional recommendations on the safety and efficacy of the procedure. The committee decision was reached by consensus.

The committee asked the NICE technical team to prepare the Final Document [FIPD] in line with their decisions.  
  
A document explaining the final recommendations is available here: <https://www.nice.org.uk/process/pmg28/chapter/the-production-of-guidance>

1. Public Consultation comments of IP1020/2 Irreversible electroporation for treating prostate cancer
   1. Part 1 – Open session
      1. The Chair welcomed the invited clinical and patient experts, external group representatives, members of the public and company representatives from AngioDynamics.
      2. The Chair asked all committee members to declare any relevant interests in relation to the item being considered.

* No conflicts of interest were declared for the technology.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
  + 1. The Chair then introduced Dhiraj Tripathi, who summarised the comments received during the consultation on the draft guidance for Irreversible electroporation for treating prostate cancer.
    2. The Chair introduced the key themes arising from the consultation responses to the Interventional Procedures Consultation Document [IPCD] received from consultees, commentators and through the NICE website.
  1. Part 2 – Closed session

Company representatives, clinical and patient experts and members of the public were asked to leave the meeting: 15:53.

* + 1. The committee then made its provisional recommendations on the safety and efficacy of the procedure. The committee decision was reached through a vote by members.
    2. The committee asked the NICE technical team to prepare the Final Document [FIPD] in line with their decisions.  
         
       A document explaining the final recommendations is available here: <https://www.nice.org.uk/process/pmg28/chapter/the-production-of-guidance>

1. Date of the next meeting

The next meeting of the Interventional Procedures Advisory Committee (IPAC) will be held on 08/12/2022 and will start promptly at 9am.